HESTER BIOSCIENCES
|
HESTER BIOSCIENCES Last 5 Year Financial Ratios History
[Consolidated]
| Mar2023 | Mar2022 | Mar2021 | Mar2020 | Mar2019 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 31.30 | 46.22 | 40.47 | 34.29 | 48.86 |
| CEPS(Rs) | 57.28 | 65.90 | 56.44 | 51.81 | 61.65 |
| DPS(Rs) | 8.00 | 10.00 | 10.00 | 6.60 | 11.00 |
| Book NAV/Share(Rs) | 328.82 | 305.61 | 268.38 | 236.36 | 208.61 |
| Tax Rate(%) | 30.18 | 26.20 | 30.75 | 24.98 | 28.43 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 18.81 | 25.32 | 31.97 | 30.23 | 38.21 |
| EBIT Margin(%) | 18.46 | 24.30 | 26.41 | 26.57 | 35.66 |
| Pre Tax Margin(%) | 14.98 | 22.58 | 23.33 | 22.55 | 31.93 |
| PAT Margin (%) | 10.46 | 16.67 | 16.16 | 16.92 | 22.85 |
| Cash Profit Margin (%) | 18.18 | 23.67 | 22.36 | 24.05 | 29.45 |
| Performance Ratios | |||||
| ROA(%) | 4.55 | 8.11 | 8.70 | 9.04 | 14.97 |
| ROE(%) | 10.39 | 16.17 | 16.16 | 16.38 | 25.59 |
| ROCE(%) | 9.60 | 14.12 | 17.33 | 16.53 | 26.64 |
| Asset Turnover(x) | 0.44 | 0.49 | 0.54 | 0.53 | 0.66 |
| Sales/Fixed Asset(x) | 0.73 | 0.82 | 0.95 | 0.83 | 0.92 |
| Working Capital/Sales(x) | 3.40 | 2.42 | 2.14 | 2.42 | 1.91 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 1.37 | 1.22 | 1.06 | 1.21 | 1.08 |
| Receivable days | 91.87 | 80.50 | 91.49 | 90.92 | 66.77 |
| Inventory Days | 109.08 | 106.00 | 107.25 | 114.27 | 92.80 |
| Payable days | 113.04 | 129.73 | 174.82 | 187.68 | 106.73 |
| Valuation Parameters | |||||
| PER(x) | 48.58 | 58.75 | 47.36 | 26.98 | 31.62 |
| PCE(x) | 26.54 | 41.20 | 33.96 | 17.85 | 25.06 |
| Price/Book(x) | 4.62 | 8.88 | 7.14 | 3.91 | 7.41 |
| Yield(%) | 0.53 | 0.37 | 0.52 | 0.71 | 0.71 |
| EV/Net Sales(x) | 5.81 | 10.67 | 8.00 | 4.82 | 7.66 |
| EV/Core EBITDA(x) | 23.52 | 34.01 | 23.37 | 14.31 | 18.12 |
| EV/EBIT(x) | 31.26 | 43.55 | 30.22 | 18.16 | 21.47 |
| EV/CE(x) | 2.31 | 4.46 | 4.17 | 2.29 | 4.55 |
| M Cap / Sales | 4.86 | 9.83 | 7.61 | 4.29 | 7.38 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 13.23 | 9.65 | 16.95 | 2.92 | 30.99 |
| Core EBITDA Growth(%) | -10.80 | 0.52 | 18.74 | -17.91 | 51.04 |
| EBIT Growth(%) | -14.06 | 1.51 | 16.45 | -23.30 | 58.10 |
| PAT Growth(%) | -29.00 | 13.79 | 11.92 | -23.82 | 76.41 |
| EPS Growth(%) | -32.28 | 14.20 | 18.03 | -29.83 | 62.24 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.96 | 0.86 | 0.46 | 0.60 | 0.51 |
| Current Ratio(x) | 1.53 | 2.01 | 2.63 | 1.91 | 2.91 |
| Quick Ratio(x) | 0.96 | 1.23 | 1.62 | 1.14 | 1.87 |
| Interest Cover(x) | 5.31 | 14.16 | 8.59 | 6.61 | 9.57 |
| Total Debt/Mcap(x) | 0.21 | 0.10 | 0.06 | 0.15 | 0.07 |
Compare Financial Ratios of peers of HESTER BIOSCIENCES
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| HESTER BIOSCIENCES | ₹1,385.8 Cr | 0.9% | -1.5% | -17.9% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹365,311.0 Cr | 3% | 2.3% | 68.2% | Stock Analytics | |
| CIPLA | ₹108,623.0 Cr | 2.5% | 0.4% | 71.7% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹99,134.3 Cr | -0.2% | -4.9% | 40.3% | Stock Analytics | |
| DIVIS LABORATORIES | ₹97,408.4 Cr | -1.6% | -7% | 23.8% | Stock Analytics | |
| ZYDUS LIFESCIENCES | ₹92,794.9 Cr | 5% | 10.4% | 109.1% | Stock Analytics | |
HESTER BIOSCIENCES Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| HESTER BIOSCIENCES | 0.9% |
-1.5% |
-17.9% |
| SENSEX | -2.6% |
-0% |
21% |
You may also like the below Video Courses
